December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network - PMC

CME Congresses .

December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network – PMC

December 1st- Prof. Florent Malard- What to expect at #ASH25 in GVHD

CME Congresses .

December 1st- Prof. Florent Malard- What to expect at #ASH25 in GVHD

November 28th- ASH 2025 Late-Breaking Preview- LBA-1: inMMyCAR Phase 1, KLN-1010 in RRMM

CME Congresses .

November 28th- ASH 2025 Late-Breaking Preview- LBA-1: inMMyCAR Phase 1, KLN-1010 in RRMM

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

CME Congresses .

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

CME Congresses .

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

CME Congresses .

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

November 13th- Dr. Jan Burger- Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL and SLL

CME Congresses .

November 13th- Dr. Jan Burger- Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL and SLL

September 26th- Prof. Mohamad Mohty- Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

CME Congresses .

September 26th- Prof. Mohamad Mohty- Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

September 24th- Prof. Robert Wynn- Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

CME Congresses .

September 24th- Prof. Robert Wynn- Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

September 19th- Prof. Samir Parekh- Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy

CME Congresses .

September 19th- Prof. Samir Parekh- Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy